Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-361 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7508.091 | 0.9928 | 0.9785 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7508.091 | 0.9918 | 0.9756 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7508.091 | 1.0032 | 1.0096 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7508.091 | 0.9621 | 0.8873 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7508.091 | 0.9334 | 0.8035 | 0.6662 | |
| MDA-MB-361 | HER2amp | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7508.091 | 0.7013 | 0.1742 | 0.6662 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7510.09 | 0.8827 | 0.7848 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7510.09 | 0.9351 | 0.8812 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7510.09 | 0.9493 | 0.9072 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7510.09 | 0.9846 | 0.9719 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7510.09 | 0.8460 | 0.7169 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7510.09 | 0.9618 | 0.9301 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7510.09 | 0.9333 | 0.8779 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7510.09 | 0.9284 | 0.8689 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7510.09 | 0.7648 | 0.5659 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7511.091 | 0.9827 | 0.9685 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7511.091 | 0.9936 | 0.9884 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7511.091 | 0.9695 | 0.9444 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7511.091 | 0.9156 | 0.8458 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7511.091 | 0.9521 | 0.9126 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7511.091 | 0.9605 | 0.9280 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7511.091 | 0.9619 | 0.9306 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7511.091 | 0.9022 | 0.8213 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7511.091 | 0.8084 | 0.6481 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7512.091 | 1.0197 | 1.0446 | 0.8817 |